{"id":27558,"date":"2024-04-10T09:23:10","date_gmt":"2024-04-10T03:53:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27558"},"modified":"2024-04-10T09:38:42","modified_gmt":"2024-04-10T04:08:42","slug":"nbf-006-promising-results","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results","title":{"rendered":"First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer"},"content":{"rendered":"\n<p>Glutathione S\u2011transferase Pi (GSTP) has a role in detoxification and anti\u2011oxidative damage response. Additionally, GSTP has a chaperone function that regulates key oncogenic pathways such as the KRAS and JNK. Since redundant pathways could compensate for the inhibition of a single kinase, targeting multiple pathways may lead to more effective therapy. NBF-006 is a novel drug product comprised of GSTP siRNA encapsulated within a proprietary lipid nanoparticle. It is designed to deliver siRNA to localized and metastatic lung tumors. As per the results presented at the AACR 2024 conference, around Thirty-eight patients with NSCLC, with or without KRAS mutation underwent treatment at varying doses of NBF-006. The drug was well tolerated with no treatment-related grade 4-5 AEs, SAEs, or DLTs. Two grade 3 events were assessed as possibly related to study treatment, anemia, and bilateral pleural effusions (both at 0.6 mg\/kg).&nbsp;<\/p>\n\n\n\n<p>The most common NBF-006-related AEs were Grade 1 or 2 infusion-related reactions (IRRs) (18 %) and nausea (11 %). IRRs (n=8 in seven patients), occurred in the first cycle and were well-managed. One patient discontinued due to recurring IRR. Cytokine elevation was only noted in this patient. No clinically meaningful complement activation nor ADA response has been observed. Apart from that, two patients (1.2 and 1.6 mg\/kg) experienced a durable PR, and 17 patients experienced SD. The disease control rate achieved was 19\/38 (59%). Patient enrichment strategies were evaluated with interesting trends observed.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"304\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-1024x304.png\" alt=\"Therapy wise Market Size of KRAS Metastatic Non-small Cell Lung Cancer in the 7MM in 2023\" class=\"wp-image-27564\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-1024x304.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-300x89.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-150x45.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-768x228.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-1536x456.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-2048x608.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10093834\/Therapy-wise-Market-Size-of-KRAS-Metastatic-Non-small-Cell-Lung-Cancer-in-the-7MM-in-2023-1568x466.png 1568w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><strong>Conclusion<\/strong><\/p>\n\n\n\n<p>NBF-006 shows long-term tolerability and promising efficacy in heavily treated pan-KRAS mutant NSCLC patients, warranting further clinical exploration alone or in combination with standard therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glutathione S\u2011transferase Pi (GSTP) has a role in detoxification and anti\u2011oxidative damage response. Additionally, GSTP has a chaperone function that regulates key oncogenic pathways such as the KRAS and JNK. Since redundant pathways could compensate for the inhibition of a single kinase, targeting multiple pathways may lead to more effective therapy. NBF-006 is a novel [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27559,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[3057,22035,20587],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-27558","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aacr","tag-aacr-2024","tag-aacr-conference","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NBF-006 Promising Results | AACR 2024<\/title>\n<meta name=\"description\" content=\"NBF-006 shows long-term tolerability and promising efficacy in heavily treated pan-KRAS mutant NSCLC patients\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NBF-006 Promising Results | AACR 2024\" \/>\n<meta property=\"og:description\" content=\"NBF-006 shows long-term tolerability and promising efficacy in heavily treated pan-KRAS mutant NSCLC patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-10T03:53:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-10T04:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092151\/nbf-006-promising-results.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NBF-006 Promising Results | AACR 2024","description":"NBF-006 shows long-term tolerability and promising efficacy in heavily treated pan-KRAS mutant NSCLC patients","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results","og_locale":"en_US","og_type":"article","og_title":"NBF-006 Promising Results | AACR 2024","og_description":"NBF-006 shows long-term tolerability and promising efficacy in heavily treated pan-KRAS mutant NSCLC patients","og_url":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-04-10T03:53:10+00:00","article_modified_time":"2024-04-10T04:08:42+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092151\/nbf-006-promising-results.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results","url":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results","name":"NBF-006 Promising Results | AACR 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092151\/nbf-006-promising-results.png","datePublished":"2024-04-10T03:53:10+00:00","dateModified":"2024-04-10T04:08:42+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"NBF-006 shows long-term tolerability and promising efficacy in heavily treated pan-KRAS mutant NSCLC patients","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/nbf-006-promising-results#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092151\/nbf-006-promising-results.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092151\/nbf-006-promising-results.png","width":466,"height":284,"caption":"nbf-006-promising-results"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10092151\/nbf-006-promising-results-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AACR<\/span>","<span class=\"advgb-post-tax-term\">AACR 2024<\/span>","<span class=\"advgb-post-tax-term\">AACR Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 10, 2024","modified":"Updated on Apr 10, 2024"},"absolute_dates_time":{"created":"Posted on Apr 10, 2024 9:23 am","modified":"Updated on Apr 10, 2024 9:38 am"},"featured_img_caption":"nbf-006-promising-results","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27558"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27558\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27559"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27558"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27558"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}